Table_1_Canakinumab for the treatment of autoinflammatory very early onset- inflammatory bowel disease.xlsx

Table_1_Canakinumab for the treatment of autoinflammatory very early onset- inflammatory bowel disease.xlsx

Introduction<p>Therapeutic options are critically needed for children with refractory very early onset inflammatory bowel disease (VEO-IBD). Our aim was to evaluate clinical response to canakinumab, an anti-IL-1β monoclonal antibody, in patients with VEO-IBD whose phenotype resembles those wit...

Full description

Saved in:
Bibliographic Details
Main Author: Eliana Shaul (13827001) (author)
Other Authors: Máire A. Conrad (13827004) (author), Noor Dawany (175164) (author), Trusha Patel (11740676) (author), Megan C. Canavan (13827007) (author), Alyssa Baccarella (3095256) (author), Sarah Weinbrom (13827010) (author), Daniel Aleynick (13827013) (author), Kathleen E. Sullivan (7553591) (author), Judith R. Kelsen (13827016) (author)
Published: 2022
Subjects:
Immunology
Applied Immunology (incl. Antibody Engineering, Xenotransplantation and T-cell Therapies)
Autoimmunity
Cellular Immunology
Humoural Immunology and Immunochemistry
Immunogenetics (incl. Genetic Immunology)
Innate Immunity
Transplantation Immunology
Tumour Immunology
Immunology not elsewhere classified
Genetic Immunology
Animal Immunology
Veterinary Immunology
canakinumab
very early onset-inflammatory bowel disease
interleukin-1
pediatric
autoinflammatory
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items